220-120-9

Applied Filters:

Keyword:'220-120-9'

Showing 1-5 of 5 results for "220-120-9" within Papers

Classification of Intracranial Stenoses: Discrepancies between Transcranial Duplex Sonography and Computed Tomography Angiography.

Leon Alexander Danyel et al.

Ultrasound in medicine & biology, 46(8), 1889-1895 (2020-05-23)

Transcranial color-coded duplex sonography (TCCS) and computed tomography angiography (CTA) are widely used to identify intracranial stenoses (ISs). We assessed concordance of IS grading between TCCS and CTA and proposed new TCCS criteria for severe IS ≥70%. One hundred two

Endurance training increases LKB1 and MO25 protein but not AMP-activated protein kinase kinase activity in skeletal muscle.

E B Taylor et al.

American journal of physiology. Endocrinology and metabolism, 287(6), E1082-E1089 (2004-08-05)

LKB1 complexed with MO25 and STRAD has been identified as an AMP-activated protein kinase kinase (AMPKK). We measured relative LKB1 protein abundance and AMPKK activity in liver (LV), heart (HT), soleus (SO), red quadriceps (RQ), and white quadriceps (WQ) from

The mechanism of atrial antiarrhythmic action of RSD1235.

David Fedida et al.

Journal of cardiovascular electrophysiology, 16(11), 1227-1238 (2005-11-24)

RSD1235 is a novel drug recently shown to convert AF rapidly and safely in patients.(1) Its mechanism of action has been investigated in a rat model of ischemic arrhythmia, along with changes in action potential (AP) morphology in isolated rat

Metformin for prevention or delay of type 2 diabetes mellitus and its associated complications in persons at increased risk for the development of type 2 diabetes mellitus.

Kasper S Madsen et al.

The Cochrane database of systematic reviews, 12, CD008558-CD008558 (2019-12-04)

The projected rise in the incidence of type 2 diabetes mellitus (T2DM) could develop into a substantial health problem worldwide. Whether metformin can prevent or delay T2DM and its complications in people with increased risk of developing T2DM is unknown.

Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.

Greg L Plosker et al.

PharmacoEconomics, 22(6), 389-411 (2004-04-22)

Repaglinide (Prandin), NovoNorm, GlucoNorm, an oral insulin secretagogue, was the first meglitinide analogue to become available for use in patients with type 2 diabetes mellitus. The drug lowers postprandial glucose excursions by targeting early-phase insulin release, an effect thought to

Page 1 of 1